1 INTRODUCTION
1.1 OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 MARKET SCOPE
1.3 RESEARCH METHODOLOGY
1.3.1 SECONDARY DATA
1.3.2 PRIMARY DATA
1.3.3 MARKET SIZE ESTIMATION
1.3.4 MARKET BREAKDOWN AND DATA TRIANGULATION
1.4 STAKEHOLDERS
1.5 CURRENCY
1.6 RESEARCH ASSUMPTIONS
1.7 LIMITATION
2 EXECUTIVE SUMMARY
3 MARKET OUTLOOK
3.1 INTRODUCTION
3.2 DROC MATRIX
3.3 MARKET CHALLENGES
3.4 MARKET SHARE ANALYSIS
3.5 COST STRUCTURE ANALYSIS
3.6 VALUE CHAIN ANALYSIS
3.7 COVID-19 IMPACT ANALYSES
4 INDUSTRY TRENDS
4.1 INTRODUCTION
4.2 PESTEL ANALYSIS
4.3 PORTER’S FIVE FORCES MODEL
4.3.1 DEGREE OF COMPETITION
4.3.2 BARGAINING POWER OF BUYERS
4.3.3 BARGAINING POWER OF SUPPLIERS
4.3.4 THREAT FROM SUBSTITUTES
4.3.5 THREAT FROM NEW ENTRANTS
5 NEUROLOGICAL BIOMARKERS TYPE ANALYSIS
5.1 INTRODUCTION
5.2 HISTORICAL MARKET TYPE ANALYSIS, 2015-2019
5.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
5.4 Y-O-Y GROWTH TREND ANALYSIS
5.5 GENOMIC
5.6 PROTEOMIC
5.7 METABOLOMIC
5.8 IMAGING
5.9 OTHERS
6 NEUROLOGICAL BIOMARKERS MARKET IMAGING TECHNIQUES ANALYSIS
6.1 INTRODUCTION
6.2 HISTORICAL MARKET IMAGING TECHNIQUES ANALYSIS, 2015-2019
6.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
6.4 Y-O-Y GROWTH TREND ANALYSIS
6.5 TRANSCRANIAL MAGNETIC STIMULATION
6.6 DIFFUSION TENSOR IMAGING
6.7 CONVENTIONAL STRUCTURAL MRI
6.8 FUNCTIONAL MAGNETIC RESONANCE IMAGING
6.9 POSITRON EMISSION TOMOGRAPHY
7 NEUROLOGICAL BIOMARKERS MARKET SERVICES ANALYSIS
7.1 INTRODUCTION
7.2 HISTORICAL MARKET SERVICES ANALYSIS, 2015-2019
7.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
7.4 Y-O-Y GROWTH TREND ANALYSIS
7.5 SAMPLE PREPARATION
7.6 ASSAY DEVELOPMENT
7.7 BIOMARKER VALIDATION AND TESTING
8 NEUROLOGICAL BIOMARKERS MARKET END-USE ANALYSIS
8.1 INTRODUCTION
8.2 HISTORICAL MARKET END-USE ANALYSIS, 2015-2019
8.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
8.4 Y-O-Y GROWTH TREND ANALYSIS
8.5 HOSPITAL LABORATORIES
8.6 INDEPENDENT CLINICAL DIAGNOSTIC CENTERS
8.7 RESEARCH ORGANIZATIONS
8.8 OTHERS
9 NEUROLOGICAL BIOMARKERS MARKET APPLICATION ANALYSIS
9.1 INTRODUCTION
9.2 HISTORICAL MARKET APPLICATION ANALYSIS, 2015-2019
9.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
9.4 Y-O-Y GROWTH TREND ANALYSIS
9.5 ALZHEIMER’S DISEASE
9.6 PARKINSON’S DISEASE
9.7 MULTIPLE SCLEROSIS
9.8 SCHIZOPHRENIA
9.9 HUNTINGTON’S DISEASE
9.10 AUTISM SPECTRUM DISORDERS
9.11 SPINAL MUSCULAR ATROPHY
9.12 DEPRESSION
9.13 OTHERS
10 GLOBAL NEUROLOGICAL BIOMARKERS REGIONAL ANALYSIS
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
10.2.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
10.2.3 Y-O-Y GROWTH TREND ANALYSIS
10.2.3.1 U.S.
10.2.3.2 Canada
10.2.3.3 Mexico
10.3 ASIA-PACIFIC
10.3.1 APAC HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
10.3.2 Y-O-Y GROWTH TREND ANALYSIS
10.3.2.1 China
10.3.2.2 Japan
10.3.2.3 Korea
10.3.2.4 India
10.3.2.5 Southeast Asia
10.4 MIDDLE EAST AND AFRICA
10.4.1 MIDDLE EAST AND AFRICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
10.4.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
10.4.3 Y-O-Y GROWTH TREND ANALYSIS
10.4.3.1 Saudi Arabia
10.4.3.2 UAE
10.4.3.3 Egypt
10.4.3.4 Nigeria
10.4.3.5 South Africa
10.5 EUROPE
10.5.1 EUROPE HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
10.5.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
10.5.3 Y-O-Y GROWTH TREND ANALYSIS
10.5.3.1 Germany
10.5.3.2 France
10.5.3.3 UK
10.5.3.4 Russia
10.5.3.5 Italy
10.6 SOUTH AMERICA
10.6.1 SOUTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
10.6.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
10.6.3 Y-O-Y GROWTH TREND ANALYSIS
10.6.3.1 Brazil
10.6.3.2 Argentina
10.6.3.3 Columbia
11 MARKET PLAYERS
11.1 ABBOTT
11.1.1 BUSINESS OVERVIEW:
11.1.2 PRODUCT PORTFOLIO
11.1.3 RECENT DEVELOPMENTS
11.1.4 SWOT ANALYSIS:
11.2 QIAGEN
11.3 MYRIAD RBM
11.4 THERMO FISHER SCIENTIFIC INC.
11.5 ATHENA DIAGNOSTICS
11.6 BIO-RAD LABORATORIES, INC.
11.7 ABASTAR MDX, INC.
11.8 ACUMEN PHARMACEUTICALS
11.9 BANYAN BIOMARKERS, INC.
11.10 ALSERES PHARMACEUTICALS, INC.
11.11 QUANTERIX
11.12 IMMUNARRAY PVT. LTD.
11.13 MERCK KGAA,
11.14 F. HOFFMANN-LA ROCHE LTD
11.15 JANSSEN GLOBAL SERVICES, LLC,
11.16 CHARLES RIVER
11.17 ADVANCED BRAIN MONITORING, INC.
11.18 NEUROSTEER
12 ABOUT US

TABLE 1 NEUROLOGICAL BIOMARKERS REGIONAL ANALYSIS, 2020–2030 (USD MILLION)
TABLE 2 GLOBAL NEUROLOGICAL BIOMARKERS MARKET, 2020–2030, (USD MILLION)
TABLE 3 NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE REGIONAL ANALYSIS, 2020–2030 (USD MILLION)
TABLE 4 GLOBAL NEUROLOGICAL BIOMARKERS HISTORICAL MARKET TYPE ANALYSIS, 2015-2019, (USD MILLION)
TABLE 5 NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 6 GLOBAL NEUROLOGICAL BIOMARKERS HISTORICAL MARKET IMAGING TECHNIQUES ANALYSIS, 2015-2019, (USD MILLION)
TABLE 7 NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE IMAGING TECHNIQUES ANALYSIS, 2020–2030 (USD MILLION)
TABLE 8 GLOBAL NEUROLOGICAL BIOMARKERS HISTORICAL MARKET SERVICES ANALYSIS, 2015-2019, (USD MILLION)
TABLE 9 NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE SERVICES ANALYSIS, 2020–2030 (USD MILLION)
TABLE 10 GLOBAL NEUROLOGICAL BIOMARKERS HISTORICAL MARKET END-USE ANALYSIS, 2015-2019, (USD MILLION)
TABLE 11 NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE END-USE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 12 GLOBAL NEUROLOGICAL BIOMARKERS HISTORICAL MARKET APPLICATION ANALYSIS, 2015-2019, (USD MILLION)
TABLE 13 NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 14 NORTH AMERICA NEUROLOGICAL BIOMARKERS HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 15 NORTH AMERICA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 16 NORTH AMERICA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE IMAGING TECHNIQUES ANALYSIS, 2020–2030 (USD MILLION)
TABLE 17 NORTH AMERICA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE SERVICES ANALYSIS, 2020–2030 (USD MILLION)
TABLE 18 NORTH AMERICA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE END-USE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 19 NORTH AMERICA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 20 U.S. NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2015–2020
TABLE 21 U.S. NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 22 U.S. NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 23 CANADA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 24 CANADA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 25 MEXICO NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 26 MEXICO NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 27 APAC NEUROLOGICAL BIOMARKERS HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 28 ASIA-PACIFIC NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 29 ASIA-PACIFIC NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE IMAGING TECHNIQUES ANALYSIS, 2020–2030 (USD MILLION)
TABLE 30 ASIA-PACIFIC NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE SERVICES ANALYSIS, 2020–2030 (USD MILLION)
TABLE 31 ASIA-PACIFIC NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE END-USE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 32 ASIA-PACIFIC NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 33 CHINA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 34 CHINA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 35 JAPAN NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 36 JAPAN NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 37 KOREA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 38 KOREA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 39 INDIA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 40 INDIA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 41 SOUTHEAST ASIA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 42 SOUTHEAST ASIA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA NEUROLOGICAL BIOMARKERS HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE IMAGING TECHNIQUES ANALYSIS, 2020–2030 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE SERVICES ANALYSIS, 2020–2030 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE END-USE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 49 SAUDI ARABIA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 50 SAUDI ARABIA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 51 UAE NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 52 UAE NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 53 EGYPT NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 54 EGYPT NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 55 NIGERIA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 56 NIGERIA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 57 SOUTH AFRICA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 58 SOUTH AFRICA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 59 EUROPE NEUROLOGICAL BIOMARKERS HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 60 EUROPE NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 61 EUROPE NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE IMAGING TECHNIQUES ANALYSIS, 2020–2030 (USD MILLION)
TABLE 62 EUROPE NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE SERVICES ANALYSIS, 2020–2030 (USD MILLION)
TABLE 63 EUROPE NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE END-USE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 64 EUROPE NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 65 GERMANY NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 66 GERMANY NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 67 FRANCE NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 68 FRANCE NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 69 UK NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 70 UK NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 71 RUSSIA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 72 RUSSIA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 73 ITALY NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 74 ITALY NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 75 SOUTH AMERICA NEUROLOGICAL BIOMARKERS HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 76 SOUTH AMERICA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 77 SOUTH AMERICA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE IMAGING TECHNIQUES ANALYSIS, 2020–2030 (USD MILLION)
TABLE 78 SOUTH AMERICA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE SERVICES ANALYSIS, 2020–2030 (USD MILLION)
TABLE 79 TABLE 82 SOUTH AMERICA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE END-USE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 80 SOUTH AMERICA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 81 BRAZIL NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 82 BRAZIL NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 83 ARGENTINA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 84 ARGENTINA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 85 COLUMBIA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 86 COLUMBIA NEUROLOGICAL BIOMARKERS CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)